WaveMan
WaveMan · Company
LEGN · Legend Biotech Corp
> Search tickers & screens ⌘K
LIVE
← All companies

LEGN Legend Biotech (LEGN) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001801198
Quote by TradingView
Form 144 · 3
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
121
13F, latest reported quarter

What the filings say about LEGN

Insiders, 180 days
-$479.6K net sold
4 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$1.6M
3 notices

Legend Biotech insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Legend Biotech Corp insiders sold a net $479.6K of stock across 5 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Foreign private issuer: most of its insiders are exempt from SEC Form 4, but some still file it; those filings are listed below, and the record may be incomplete.

Insider
Filed
Shares
Value
Since filing
Sanders Corazon (Corsee) D.
Director
SELL
2026-10-01 SECtraded 2026-09-29
27,370
$258.9K
+9.8%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 51.9% of the 52,731 shares held after it.
  • 1 other insider sold within 30 days.
  • 121 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Sanders Corazon (Corsee) D. sold about $258.9K of LEGN on Sep 29, 2026, the largest insider sale at the company on our record; 1 other insider sold within 30 days and 121 funds added in the latest 13F quarter.
Santos Carlos E
Chief Financial Officer
SELL
2026-09-23 SECtraded 2026-09-21
5,430
$49.6K
+7.0%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 38.1% of the 14,246 shares held after it.
  • 1 other insider sold within 30 days.
  • 121 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Santos Carlos E sold about $49.6K of LEGN on Sep 21, 2026; 1 other insider sold within 30 days and 121 funds added in the latest 13F quarter.
Casey Patrick John
Director
SELL
2026-07-02 SECtraded 2026-06-30
6,000
$88.8K
-27.3%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 12.3% of the 48,604 shares held after it.
  • 1 other insider sold within 30 days.
  • 121 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Casey Patrick John sold about $88.8K of LEGN on Jun 30, 2026, the largest insider sale at the company on our record; 1 other insider sold within 30 days and 121 funds added in the latest 13F quarter.
Huang Ying
Chief Executive Officer
SELL
2026-06-29 SECtraded 2026-06-25
5,566
$82.3K
-29.4%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Mar 25, 2026.
  • The trade is 2.3% of the 241,872 shares held after it.
  • 1 other insider sold within 30 days.
  • 121 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Huang Ying sold about $82.3K of LEGN on Jun 25, 2026; 1 other insider sold within 30 days and 121 funds added in the latest 13F quarter.
Huang Ying
Chief Executive Officer
SELL
2026-03-27 SECtraded 2026-03-25
9,936
$87.1K
+17.8%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 4.0% of the 247,438 shares held after it.
  • No other insider sold within 30 days.
  • 121 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Huang Ying sold about $87.1K of LEGN on Mar 25, 2026, the largest insider sale at the company on our record; 121 funds added in the latest 13F quarter.
5 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$479.6K over 180 days
-$308.6K over 90 days
below 55% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
121 funds bought in last quarter
more than 76% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
18.0% of the float short (float per yahoo 2026-10-26) · 7.1 days to cover · settled 2026-09-30
below 52% of Pharma & Biotech
What changed in the last 30 days
Oct 1Director Sanders Corazon (Corsee) D. sold $258.9K (Sep 29)
Sep 29Director Sanders Corazon (Corsee) D. filed to sell $258.9K by Sep 29 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch LEGN

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-35.6%12M
-47%-27%-6%+15%2025-102025-122026-022026-042026-062026-082026-10 2026-09-29 · Sanders Corazon (Corsee) D. sold $258.9K2026-06-30 · Casey Patrick John sold $88.8K2026-03-25 · Huang Ying sold $87.1K2026-06-25 · Huang Ying sold $82.3K2026-09-21 · Santos Carlos E sold $49.6K2026-09-29 · Sanders Corazon (Corsee) D. filed to sell $258.9K2026-09-22 · Huang Ying filed to sell $1.3M2026-09-22 · Santos Carlos E filed to sell $50.9K2026-06-30 · Casey Patrick John filed to sell $88.8K2026-06-26 · Huang Ying filed to sell $79.0K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns LEGN: institutional holders (13F)

13F holdings, latest reported quarter
FMR LLC
29,093,899 sh
$840.2M
DEERFIELD MANAGEMENT COMPANY, L.P.
8,137,638 sh
$235.0M
MONTANOVA CAPITAL, LLC
7,070,000 sh
$204.2M
HHLR ADVISORS, LTD.
5,984,550 sh
$172.8M
BlackRock, Inc.
4,726,534 sh
$136.5M

Congress trades in LEGN

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

LEGN planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Sanders Corazon (Corsee) D.
Filed 2026-09-29
$258.9K
Huang Ying
Filed 2026-09-22
$1.3M
Santos Carlos E
Filed 2026-09-22
$50.9K
Casey Patrick John
Filed 2026-06-30
$88.8K
Huang Ying
Filed 2026-06-26
$79.0K

LEGN mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Select Pharmaceuticals Portfolio
$68.0M position · as of 2026-05-31
4.5%
Global X Genomics & Biotechnology ETF
$2.3M position · as of 2026-05-31
4.0%
Matthews Emerging Markets Discovery Active ETF
$730.6K position · as of 2026-06-30
3.2%
Matthews Emerging Markets Small Companies Fund
$13.6M position · as of 2026-06-30
3.1%
Tema Oncology ETF
$5.3M position · as of 2026-05-31
3.0%
Fidelity Disruptive Medicine ETF
$940.1K position · as of 2026-05-31
2.3%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $479.6K sold by insiders over 180 days, 121 funds added last quarter, $1.6M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

LEGN financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
fewer than four consecutive quarters of operating cash flow
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
n/a
no equity line filed
Return on assets
-17.4%
TTM net income over average of 2024-12-31 and 2025-12-31
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Enterprise value
n/a
no debt line filed
FCF yield
n/a
fewer than four consecutive quarters of operating cash flow
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Net income-$296.8M-$177.0M-$518.3M-$446.3M
SEC XBRL, fiscal years, as known on 2026-10-28

LEGN Stock Sonar score 3/7 axes

Find similar shapesCompare

LEGN ranks highest on institutional and government (68th percentile) and insider conviction (21st), and lowest on risk and compliance (18th), among Pharma & Biotech peers.

Insider conviction
21
Inputs
  • Net Form 4 buying (codes P and S), 180d-$480K · 42 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
68
Inputs
  • Funds adding, latest quarter121 · 76 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$380K · 61 pct, sector of 133
Risk and compliance
18
Inputs
  • Short interest, % of float+18.0% · 18 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
4 not measured: Profitability, Financial health, Growth, US patents
  • Profitability needs 2 of 4 inputs, 1 present: fewer than four consecutive quarters of operating income; no equity line filed
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

LEGN filings, in plain words

Are Legend Biotech insiders buying or selling LEGN?

In the 180 days to 2026-10-28, Legend Biotech insiders were net sellers, a net $479.6K across purchases and sales reported on Form 4, by 4 sellers.

Are there planned insider sales of LEGN?

Yes. 3 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $1.6M of stock; the latest, by Sanders Corazon (Corsee) D., was filed 2026-09-29.

Read the full summary

In the 180 days to 2026-10-28, Legend Biotech insiders were net sellers of LEGN, a net $479.6K across purchases and sales reported on Form 4 by 4 sellers. None of the 4 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 3 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $1.6M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies